Reversible Cardiomyopathy Associated with Multicentric Castleman Disease: Successful Treatment with Tocilizumab, an Anti—Interleukin 6 Receptor Antibody

Multicentric Castleman disease (MCD) is a rare lymphoproliferative disorder characterized by systemic lymphadenopathy and inflammatory symptoms that are associated with the overproduction of interleukin 6 (IL-6). Although several nonlym-phoid organs can also be damaged in MCD, only a few cases with cardiac complications have been reported to date. We report a case of congestive heart failure in a female patient with MCD. On admission, her echocardiogram revealed a dilated and diffusely hypokinetic left ventricle. No stenosis was evident in the coronary angiogram. A histopathologic examination of a myocardial biopsy specimen showed mildly hypertrophic myocytes without infiltration of plasma cells or amyloid deposits. Repeated administration of an anti—IL-6 receptor antibody, tocilizumab (formerly known as MRA), gradually improved the ventricular wall motion over 6 months without any additional treatment for heart failure, suggesting the involvement of IL-6 in the pathogenesis of her cardiomyopathy. This report is the first of MCD complicated by heart failure treated successfully with tocilizumab. Administering tocilizumab in cases of MCD with unexplained cardiac dysfunction is worthwhile, because such a complication could be reversible.

[1]  義征 大杉,et al.  キャッスルマン病治療薬，遺伝子組換えヒト化抗ヒトインターロイキン-6受容体抗体（トシリズマブ）の薬理学的特徴と臨床効果 , 2005 .

[2]  L. Staudt,et al.  Clinical Trials and Observations , 2007 .

[3]  M. Decramer,et al.  Interleukin-6 Causes Myocardial Failure and Skeletal Muscle Atrophy in Rats , 2005, Circulation.

[4]  M. Bower,et al.  Fifty years of multicentric Castleman's disease , 2004, Acta oncologica.

[5]  Y. Fujio,et al.  Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure , 2004, Heart and Vessels.

[6]  K. Murata,et al.  Scintigraphic evaluation of cardiac metabolism in multicentric Castleman's disease. , 2004, Internal medicine.

[7]  T. Hibi,et al.  A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. , 2004, Gastroenterology.

[8]  T. Kanda,et al.  Interleukin-6 and cardiovascular diseases. , 2004, Japanese heart journal.

[9]  C. Rücker-Martin,et al.  Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation. , 2003, Cardiovascular research.

[10]  R. Kennedy,et al.  JAK2/STAT3, Not ERK1/2, Mediates Interleukin-6-induced Activation of Inducible Nitric-oxide Synthase and Decrease in Contractility of Adult Ventricular Myocytes* , 2003, The Journal of Biological Chemistry.

[11]  T. Therneau,et al.  POEMS syndrome: definitions and long-term outcome. , 2003, Blood.

[12]  M. Shimizu,et al.  Crow-Fukase syndrome associated with high-output heart failure. , 2002, Internal medicine.

[13]  T. Nakata,et al.  Crow-Fukase syndrome with ischemic cardiomyopathy. , 2001, Internal medicine.

[14]  P. Gabriele,et al.  Activation of the cardiac interleukin‐6 system in advanced heart failure , 2001 .

[15]  K. R. Bennett,et al.  Elevated plasma concentration of vascular endothelial growth factor in cardiac myxoma. , 2001, The Journal of thoracic and cardiovascular surgery.

[16]  芳子 植村,et al.  心エコー上拡張型心筋症様の変化を来したMulticentric Castleman's Diseaseの1例 , 2001 .

[17]  T. Hirano,et al.  Signaling mechanisms through gp130: a model of the cytokine system. , 1997, Cytokine & growth factor reviews.

[18]  T. Kishimoto,et al.  Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[19]  T. Suzuki,et al.  An interleukin-6 secreting myxoma in a hypertrophic left ventricle. , 1994, Chest.

[20]  L. Cripe,et al.  Presentation of multicentric Castleman's disease with sicca syndrome, cardiomyopathy, palmar and plantar rash. , 1993, The Journal of rheumatology.

[21]  K. Yasukawa,et al.  IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. , 1993, Science.

[22]  Simon C Watkins,et al.  Negative inotropic effects of cytokines on the heart mediated by nitric oxide. , 1992, Science.

[23]  B. Castleman,et al.  Localized mediastinal lymph‐node hyperplasia resembling thymoma , 1956, Cancer.

[24]  S. Nakatani,et al.  [Multicentric Castleman's disease with reversible left ventricular diffuse hypokinesis]. , 2001, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[25]  H. Scheld,et al.  Activation of the cardiac interleukin-6 system in advanced heart failure. , 2001, European journal of heart failure.

[26]  T. Komori,et al.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. , 1989, Blood.